查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606625

限制性胜肽药物市场：按胜肽类型、最终用户划分 - 全球预测 2025-2030

Constrained Peptide Drugs Market by Peptide Type (Macrocyclic, Stapled), End-User (Hospitals & Clinics, Pharmaceutical Companies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年限制性胜肽药物市场价值为12.2亿美元，预计到2024年将达到14.7亿美元，复合年增长率为21.44%，到2030年将达到47.6亿美元。

限制性胜肽药物是生物技术疗法的创新子集，涉及化学或结构限制，因此与传统胜肽相比具有增强的稳定性和特异性。这一快速增长的领域至关重要，因为它有可能透过针对细胞内以前被认为「无法治疗」的蛋白质-蛋白质相互作用来解决未满足的医疗需求。其应用涵盖肿瘤学、代谢疾病和自体免疫疾病，在这些治疗领域具有广泛的最终用途。市场成长是由研发投资的增加、胜肽合成技术的进步以及标靶疾病的增加所推动的。特别是，这些药物的精确度和功效为个人化医疗提供了巨大潜力，进一步推动了需求。

主要市场统计
基准年[2023] 12.2亿美元
预测年份 [2024] 14.7亿美元
预测年份 [2030] 47.6亿美元
复合年增长率（%） 21.44%

最近的机会来自技术进步，例如药物发现中的人工智慧，可以简化可行的受限胜肽的识别，以及生物技术公司和学术界之间促进创新的策略联盟。公司应该投资这些伙伴关係和先进的计算工具，以保持竞争力。然而，挑战依然存在，包括高昂的开发和製造成本、严格的监管要求以及扩大胜肽药物生产的固有复杂性。

创新应着重于改进合成技术，例如固相胜肽合成（SPPS）以及与小分子和生技药品的杂合反应，以改善药物特性。此外，探索新的标靶和递送系统可以扩大限制胜肽的应用范围。

市场极为活跃，併购导致竞争日益激烈。最佳策略包括继续参与合作研究计划并利用最尖端科技进行药物设计。在利用这些机会的同时，企业应致力于有效地掌握监管发展动态，以缩短上市时间并确保永续成长和市场领导地位。平衡开创性药物开发的投资和克服物流限制对于释放限制性胜肽药物市场的潜力至关重要。

市场动态：揭示快速发展的限制性胜肽药物市场的关键市场洞察

供应和需求的动态交互作用正在改变限制性胜肽药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界慢性病的增加
    • 胜肽化学和合成技术的不断进步
    • 对製造生技药品和个人化药物的需求增加
  • 市场限制因素
    • 与胜肽药物开发相关的高成本
  • 市场机会
    • 加强研发力度，开发新型限制性胜肽药物
    • 政府对包括限制性胜肽药物在内的创新治疗方法的支持
  • 市场问题
    • 多肽生物利用度低的问题

波特五力：驾驭限制性胜肽药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解限制性多肽药物市场的外部影响

外部宏观环境因素在塑造限制性胜肽药物市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解限制性胜肽药物市场的竞争格局

对限制性胜肽药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：限制性胜肽药物市场供应商的绩效评估

FPNV定位矩阵是评估限制性胜肽药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：在限制性胜肽药物市场中製定成功之路

对于旨在加强其在全球市场的影响力的公司来说，限制性胜肽药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3. 塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球慢性病发生率正在上升
      • 胜肽化学和合成技术的不断进步
      • 对生物製药和个人化药品製造的需求不断增长
    • 抑制因素
      • 与胜肽药物开发相关的高成本
    • 机会
      • 加强限制性胜肽药物新开发研发
      • 政府对创新治疗方法的支持（包括限制性胜肽药物）
    • 任务
      • 胜肽生物有效性低所引起的问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 限制性多肽药物市场：按多肽类型

  • 介绍
  • 大环
  • 吻合术

第七章 限制性胜肽药物市场：依最终使用者分类

  • 介绍
  • 医院/诊所
  • 製药公司

第八章 北美和南美限制性多肽药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太限制性多肽药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲限制性多肽药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Bicycle Therapeutics, Inc.
  • Biosynth Ltd
  • IRBM SpA
  • PeptiDream Co., Ltd.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • UCB SA
Product Code: MRR-5C6F41F5AF46

The Constrained Peptide Drugs Market was valued at USD 1.22 billion in 2023, expected to reach USD 1.47 billion in 2024, and is projected to grow at a CAGR of 21.44%, to USD 4.76 billion by 2030.

Constrained peptide drugs are an innovative subset of biotechnology therapeutics characterized by their enhanced stability and specificity compared to traditional peptides, due to the inclusion of chemical or structural constraints. This burgeoning segment is vital due to its potential to address unmet medical needs by targeting challenging intracellular protein-protein interactions, previously deemed "undruggable." Their applications span oncology, metabolic disorders, and autoimmune diseases, providing significant end-use scope in these therapeutic areas. Market growth is fueled by rising investments in R&D, advancements in peptide synthesis technologies, and increasing prevalence of targeted diseases. Notably, the precision and potency of these drugs offer substantial promise in personalized medicine, further driving demand.

KEY MARKET STATISTICS
Base Year [2023] USD 1.22 billion
Estimated Year [2024] USD 1.47 billion
Forecast Year [2030] USD 4.76 billion
CAGR (%) 21.44%

Recent opportunities arise from technological advancements such as artificial intelligence in drug discovery, which can streamline the identification of viable constrained peptides, and strategic collaborations between biotech firms and academia, facilitating innovation. Companies should invest in these partnerships and advanced computational tools to stay competitive. However, challenges persist, primarily the high cost of development and production, stringent regulatory requirements, and the inherent complexity of scaling peptide drug manufacturing.

Innovation should focus on improving synthesis techniques, such as solid-phase peptide synthesis (SPPS) and hybridization with small molecules or biologics to enhance drug properties. Moreover, exploring novel targets and delivery systems can expand the applicability of constrained peptides.

The market is highly dynamic, with a landscape marked by competitive consolidation through mergers and acquisitions. The best strategy involves continuous engagement in collaborative research initiatives and leveraging cutting-edge technologies for drug design. While capitalizing on these opportunities, companies should also aim to navigate regulatory pathways efficiently to reduce time-to-market, ensuring sustained growth and market leadership. Balancing investment between pioneering drug development and overcoming logistical limitations will be crucial for seizing the potential within the constrained peptide drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Constrained Peptide Drugs Market

The Constrained Peptide Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of chronic diseases globally
    • Continuous advancements in peptide chemistry and synthesis techniques
    • Increasing demand for manufacturing of biologics and personalized medicines
  • Market Restraints
    • High cost associated with the drug development of peptides
  • Market Opportunities
    • Increasing research & development to develop novel constrained peptide drugs
    • Availability of government support for innovative therapies, including constrained peptide drugs
  • Market Challenges
    • Issues with low bioavailability of peptides

Porter's Five Forces: A Strategic Tool for Navigating the Constrained Peptide Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Constrained Peptide Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Constrained Peptide Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Constrained Peptide Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Constrained Peptide Drugs Market

A detailed market share analysis in the Constrained Peptide Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Constrained Peptide Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Constrained Peptide Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Constrained Peptide Drugs Market

A strategic analysis of the Constrained Peptide Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Constrained Peptide Drugs Market, highlighting leading vendors and their innovative profiles. These include Bicycle Therapeutics, Inc., Biosynth Ltd, IRBM S.p.A., PeptiDream Co., Ltd., Pfizer Inc., Protagonist Therapeutics, Inc., and UCB S.A.

Market Segmentation & Coverage

This research report categorizes the Constrained Peptide Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Peptide Type, market is studied across Macrocyclic and Stapled.
  • Based on End-User, market is studied across Hospitals & Clinics and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic diseases globally
      • 5.1.1.2. Continuous advancements in peptide chemistry and synthesis techniques
      • 5.1.1.3. Increasing demand for manufacturing of biologics and personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the drug development of peptides
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research & development to develop novel constrained peptide drugs
      • 5.1.3.2. Availability of government support for innovative therapies, including constrained peptide drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Issues with low bioavailability of peptides
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Constrained Peptide Drugs Market, by Peptide Type

  • 6.1. Introduction
  • 6.2. Macrocyclic
  • 6.3. Stapled

7. Constrained Peptide Drugs Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Pharmaceutical Companies

8. Americas Constrained Peptide Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Constrained Peptide Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Constrained Peptide Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bicycle Therapeutics, Inc.
  • 2. Biosynth Ltd
  • 3. IRBM S.p.A.
  • 4. PeptiDream Co., Ltd.
  • 5. Pfizer Inc.
  • 6. Protagonist Therapeutics, Inc.
  • 7. UCB S.A

LIST OF FIGURES

  • FIGURE 1. CONSTRAINED PEPTIDE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CONSTRAINED PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CONSTRAINED PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONSTRAINED PEPTIDE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONSTRAINED PEPTIDE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY MACROCYCLIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STAPLED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. CONSTRAINED PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. CONSTRAINED PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023